CARDIOL THERAPEUTICS
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
CARDIOL THERAPEUTICS
Industry:
Biotechnology Life Science Nanotechnology
Founded:
2017-01-01
Address:
Oakville, Ontario, Canada
Country:
Canada
Website Url:
http://www.cardiolrx.com
Total Employee:
11+
Status:
Active
Contact:
289.910.0850
Email Addresses:
[email protected]
Total Funding:
76.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Employees Featured
Founder
Stock Details
Investors List
Raymond James
Raymond James investment in Post-IPO Equity - Cardiol Therapeutics
Canaccord Genuity Group
Canaccord Genuity Group investment in Post-IPO Equity - Cardiol Therapeutics
AlbaCore Capital
AlbaCore Capital investment in Post-IPO Equity - Cardiol Therapeutics
Echelon Wealth Partners
Echelon Wealth Partners investment in Post-IPO Equity - Cardiol Therapeutics
Official Site Inspections
http://www.cardiolrx.com Semrush global rank: 7.26 M Semrush visits lastest month: 548
- Host name: 65.39.134.189
- IP address: 65.39.134.189
- Location: Toronto Canada
- Latitude: 43.6683
- Longitude: -79.4205
- Timezone: America/Toronto
- Postal: M6G
More informations about "Cardiol Therapeutics"
Company - Cardiol Therapeutics
The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart …See details»
Contact Us - Cardiol Therapeutics
Email: [email protected] Tel: +1 (289) 910-0850. Cardiol Therapeutics Inc. 602-2265 Upper Middle Road East Oakville, Ontario Canada L6H 0G5 . For investor relations and media …See details»
Cardiol Therapeutics Inc. - LinkedIn
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti …See details»
Cardiol Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 289.910.0850 Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart …See details»
Cardiol Therapeutics Inc (CRDL-T) Profile - The Globe and Mail
Nov 25, 2002 Cardiol Therapeutics Inc 2265 Upper Middle Road East Suite 602 Oakville ON L6H 0G5 CAN P: 289-910-0850 https://www.cardiolrx.comSee details»
Cardiol Therapeutics advances heart disease treatments
6 hours ago The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. This designation is given to …See details»
Cardiol Therapeutics Company Description - Stock Analysis
Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute …See details»
Cardiol Therapeutics Inc. - VentureRadar
CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (5 ppm). The Company also plans to commercialize CardiolRx in the billion-dollar market for medicinal …See details»
Cardiol Therapeutics - Overview, News & Similar companies
Cardiol Therapeutics contact info: Phone number: (289) 910-0850 Website: www.cardiolrx.com What does Cardiol Therapeutics do? Cardiol Therapeutics Inc., a clinical-stage life sciences …See details»
Cardiol Therapeutics Announces Year-End 2024 Update on …
17 hours ago Treatment with CardiolRx™ was shown to be safe and well tolerated. Based on the compelling results from MAvERIC-Pilot, in October 2024, Cardiol announced advancing to …See details»
Cardiol Therapeutics 2025 Company Profile: Stock ... - PitchBook
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of …See details»
Cardiol Reports Positive Phase II Data, Advances to Phase III ...
6 hours ago Cardiol Therapeutics (NASDAQ: CRDL) a fourni sa mise à jour opérationnelle de fin d'année 2024, mettant en avant des progrès significatifs dans ses programmes cliniques. …See details»
Cardiol Therapeutics, Inc. (Cardiol Therapeutics, Inc.) - 药物管线_专 …
了解Cardiol Therapeutics, Inc. (Cardiol Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 42篇新闻，疾病领域:神经系统疾病，血液及淋巴系统疾病，肿瘤， …See details»
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses …
Oct 22, 2024 Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), a clinical-stage life sciences company focused on innovative heart disease therapies, and Phase II ARCHER trial, …See details»
CardiolRx - Drug Targets, Indications, Patents - Synapse - Patsnap
Jun 13, 2023 Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with …See details»
Cardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial …
Oct 22, 2024 “CardiolRx™ has been shown experimentally to inhibit assembly and activation of the NLRP3 inflammasome and the subsequent generation of IL-1, and following oral …See details»
Cardiol Therapeutics Announces Pre-Clinical Study Results …
Oct 3, 2022 Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac …See details»
Pipeline - Cardiol Therapeutics
CardiolRx™ (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting …See details»
Cannabidiol Formulation Granted Orphan Drug Designation for
Feb 15, 2024 The tolerance, safety, and effect of CardiolRx in patients with recurrent pericarditis is currently being investigated in the phase 2, open-label MAvERIC-Pilot study …See details»
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 …
Aug 26, 2020 CardiolRx is an extra strength formulation of pharmaceutical cannabidiol that has been formulated to set the highest industry standard for purity, consistency, and stability. …See details»